Opus Genetics (IRD) Times Interest Earned (2020 - 2026)

Opus Genetics (IRD) reported Times Interest Earned of -$208.17 for Q1 2026, down 10.88% quarter-over-quarter from -$187.75 in Q4 2025.

Opus Genetics (IRD) Times Interest Earned (2020 - 2026) Analysis & Trends

Opus Genetics (IRD) has 5 years of Times Interest Earned data on file, last reported at -$208.17 in Q1 2026.

Times Interest Earned for Q1 2026 came in at -$208.17, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$217.34 (changed N/A YoY), and the FY2025 annual result was -$299.22, changed N/A from the prior year.
Times Interest Earned declined to -$208.17 in Q1 2026 per IRD's latest filing, from -$187.75 in the prior quarter.
Over five years, Times Interest Earned peaked at -$122.22 in Q3 2025 and troughed at -$1301.6 in Q1 2022.
A 3-year average of -$610.85 and a median of -$208.17 in 2026 frame the typical range for Times Interest Earned.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	3.58
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	11.50
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-258.33
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	547.67
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	11.79
10	Opus Genetics	355.39 Mn	295.43 Mn	-	-208.17

Download Data